Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Learn More

Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations

LEARN MORE

RECENT PRESS RELEASES

02/06/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
02/06/2020 - Pfizer Establishes New Program to Support Continued Biotechnology Innovation
29/05/2020 - Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
29/05/2020 - Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
22/05/2020 - Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
19/05/2020 - Pfizer Prices $4,000,000,000 Debt Offering
15/05/2020 - Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
14/05/2020 - Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
13/05/2020 - Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
12/05/2020 - New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
12/05/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
08/05/2020 - Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
05/05/2020 - Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
04/05/2020 - New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
01/05/2020 - Pfizer Receives Positive CHMP Opinion for DAURISMO®(glasdegib)for Certain Adult Patients with Newly Diagnosed or Secondary Acute Myeloid Leukemia (AML)